Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 120.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,667 shares of the conglomerate’s stock after acquiring an additional 2,001 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Danaher were worth $724,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in DHR. Sierra Ocean LLC lifted its position in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Red Tortoise LLC increased its stake in Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in Danaher in the 2nd quarter valued at about $40,000. Costello Asset Management INC purchased a new stake in Danaher in the 1st quarter valued at about $41,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its stake in Danaher by 53.8% in the 1st quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after buying an additional 71 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.
Insiders Place Their Bets
In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Danaher
Danaher Stock Up 0.3%
Danaher stock opened at $215.63 on Friday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm has a market capitalization of $152.31 billion, a price-to-earnings ratio of 44.46, a P/E/G ratio of 3.28 and a beta of 0.77. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a 50 day simple moving average of $203.41 and a 200 day simple moving average of $199.47.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the business earned $1.71 EPS. Danaher’s revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is currently 26.39%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- How to find penny stocks to invest and tradeĀ
- Amazon Earnings: 3 Catalysts That Could Drive Shares to $300
- How to Choose Top Rated Stocks
- Why Chipotle Stock May Bounce After a Brutal Sell-Off
- What Are the U.K. Market Holidays? How to Invest and Trade
- Why VGT May Be a Smarter Bet Than Chasing Individual Tech Stocks
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
